Latest Articles

Publication Date
All News Scientific
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care - The National Law Review

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Endometriosis Care The National Law Review

Published: March 24, 2026, 2:19 p.m.
Read Full Article
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace

Published: March 23, 2026, 12:47 p.m.
Read Full Article
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire

Published: March 23, 2026, 11:30 a.m.
Read Full Article
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - Digital Journal

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis Digital Journal

Published: March 18, 2026, 12:41 p.m.
Read Full Article
Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - ACCESS Newswire

Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis ACCESS Newswire

Published: March 18, 2026, 10:13 a.m.
Read Full Article
FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - FinancialContent

FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis FinancialContent

Published: March 18, 2026, 10 a.m.
Read Full Article
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update The Manila Times

Published: March 16, 2026, 12:15 p.m.
Read Full Article
TCF21 promotes epithelial-to-mesenchymal transition and cytoskeleton reorganization in uterine development and endometriosis.

Endometriosis is a common gynecological disease associated with pelvic pain and infertility. Despite several existing theories, the etiology and molecular mechanisms of endometriosis remain to be investigated. Here we report …

Published: March 5, 2026, midnight
Read Full Article
Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com

Jefferies reiterates Acrivon Therapeutics stock rating on trial data Investing.com

Published: March 2, 2026, 9:32 p.m.
Read Full Article
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World

Published: March 2, 2026, 6:50 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!